Renal cell cancer and positron emission tomography - An evolving diagnostic and therapeutic relationship

Current Medical Imaging Reviews

Volumn 3, Issue 1, 2007, Pages 17-26

  Lawrentschuk, Nathan ^a   Bolton, Damien M ^a   Davis, Ian D ^a   Scott, Andrew M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antibodies monoclonal; Diagnostic imaging; Fluorodeoxyglucose F18; Positron emission tomography; Radio immunodetection; Renal cell carcinoma

Indexed keywords

ANTIBODIES; CELLS; COMPUTERIZED TOMOGRAPHY; CYTOLOGY; DIAGNOSIS; ELECTRONS; POSITRONS; RADIOACTIVE TRACERS;

DIAGNOSTIC IMAGING; F-FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F18; IMMUNODETECTION; METHOD OF DIAGNOSING; RADIO-IMMUNODETECTION; RELIABLE METHODS; RENAL CELL CANCERS; RENAL CELL CARCINOMA;

POSITRON EMISSION TOMOGRAPHY;

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ACETIC ACID C 11; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBON 11; CHOLINE C 11; CONTRAST MEDIUM; DACTINOMYCIN; EPIPODOPHYLLOTOXIN DERIVATIVE; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 2; IODINE 124; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY G250 I 131; MONOCLONAL ANTIBODY G250 ZR 89; NITROGEN 13; OXYGEN 15; TAXANE DERIVATIVE; TECHNETIUM 99M; TRACER; VINCA ALKALOID; YTTRIUM 86;

BONE SCINTISCANNING; CANCER RESISTANCE; CANCER STAGING; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG ACCUMULATION; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; ECHOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMAGE QUALITY; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; KIDNEY CANCER; KIDNEY CARCINOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; PARTIAL NEPHRECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 43949143142     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340507779940372     Document Type: Review

References (61)

1. Brush JP. Positron emission tomography in urological malignancy. Curr Opin Urol 2001; 11: 175-9.
2. Hara T: 18F-fluorocholine: a new oncologic PET tracer. J Nuel Med 2001; 42: 1815-7.
3. Hara T, Kondo T, Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided sterootactic biopsy sampling of gliomas. J Neurosurg 2003; 99: 474-9.
4. Vansteenkiste JF, Stroobants SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am 2004; 18: 269-88.
5. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with 18F-fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212.
6. Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia in human renal tumours using F-fluoromisonidazole positron emission tomography. BJU Int 2005; 96: 540-6.
7. Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995; 36: 1595-601.
8. Israel GM, Bosniak MA: Renal imaging for diagnosis and staging of renal cell carcinoma. Urol Clin North Am 2003; 30: 499-514.
9. Hu H, He HD, Foley WD, et al. Four Multidetector-Row Helical CT: Image Quality and Volume Coverage Speed. Radiology 2000; 215: 55-62.
10. Oto A, Tamm EP, Szklaruk J. Multidetector row CT of the liver. Radiol Clin North Am 2005; 43: 827-48, vii.
11. Foley WD: Special Focus Session. Multidetector CT: Abdominal Visceral Imaging. Radiographics 2002; 22: 701-719.
12. Sheth S, Scatarige JC, Horton KM, et al. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics 21 Spec No: S237-54, 2001.
13. Johnson CD, Dunnick NR, Cohan RH, et al. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 1987; 148: 59-63.
14. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 75 Spec No: S24-30, 2002.
15. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 2003; 33: 193-204.
16. Gambhir SS, Czemin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42. 1S-93S.
17. Wahl RL, Harney J, Hutchins G, et al. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol 1991; 146: 1470-4.
18. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825-30.
19. Kocher F, Grimmel S, Hautmann R, et al. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med 1994; 35 (suppl): 223P-224P.
20. Montravers F, Graheck D, Kerrou K, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41: 78-84.
21. Safaei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002; 57: 56-62.
22. Hoh CK, Figlin R, Belldegrun A. Evaluation of renal cell carcinoma with whole-body FDG PET. J Nucl Med 1996; 37: 141P.
23. Goldberg MA, Mayo-Smith WW, Papanicolaou N, et al. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52: 510-5.
24. Lang O, Brouwers A, Mergenthaler H, et al. Value of whole-body 18F-FDG PET in metastatic renal cell carcinoma- correlation with tumour aggressiveness. J Nuc Med 2002; 41: 117P.
25. Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 2003; 3: 303-9.
26. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005; 46 Suppl 1: 164S-71S.
27. Humm JL, Rosenfeld A, Del Guerra A: From PET detectors to PET scanners. Eur J Nucl Med Mol Imaging 2003; 30: 1574-97.
28. Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003; 44: 1282-3.
29. Oosterwijk E, Brouwers A, Boerman OC, et al. Monoclonal antibody therapy of kidney cancer. Cancer Treat Res 2003; 116: 199-212.
30. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177-86.
31. Nishiyama K, Shirahama T, Yoshimura A, et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 1993; 71: 3611-9.
32. Schaub TP, Kartenbeck J, Konig J, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999; 10: 1159-69.
33. Oosterwijk E, Divgi CR, Brouwers A, et al. Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am 2003; 30: 623-31.
34. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Rea 1990; 50: 814s-819s.
35. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022-32.
36. Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 1990; 8: 1894-906.
37. Lee FT, Hall C, Rigopoulos A, et al. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med 2001; 42: 764-9
38. Verel I, Visser GW, Boellaard R, et al. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med 2003; 44: 1271-81.
39. Tolmachev V, Orlova A, Lundqvist H. Approaches to improve cellular retention of radiohalogen labels delivered by intarnalising tumour-targeting proteins and peptides. Curr Med Chem 2003; 10: 2447-60.
40. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 2003; 63: 111-8.
41. Scott AM, Cebon J: Clinical promise of tumour immunology, Lancet 1997; 349 Suppl 2: SIII9-22.
42. Stone JE, Parker R, Gilks CB, et al. Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis. Eur J Gynaecol Oncol 2005; 26: 31-5.
43. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity, J Histochem Cytochem, 1998, pp 497-504.
44. Hyrsl L, Kawaciuk I, Zavada J, et al. Detection methods of soluble form of carbonic anhydrase IX (CA IX) in blood serum and in urine of renal cell carcinoma patients. Euro Urol 2004; 3: 181.
45. Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 2003; 9: 5666-74.
46. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation, Am J Pathol, 1998, pp 279-85.
47. Dorai T, Sawczuk IS, Pastorek J, et al. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005; 41: 2935-47.
48. Uemura H, Nakagawa Y. Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 741-6.
49. Liao SY, Aurelio ON, Jan K, et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997; 57: 2827-31.
50. Murakami Y, Kanda K, Tsuji M, et al. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999; 83: 743-7.
51. Steffens MG, Oosterwijk E, Kranenborg MH, et al. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med 1999; 40: 829-36.
52. Oosterwijk E, Debruyne FM. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J Urol 1995; 13: 186-90.
53. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell cardmoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 1529-37.
54. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine- 131 -labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4: 2729-39.
55. Divgi CR, O'Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004; 45: 1412-21.
56. Lam JS, Pantuck AJ, Belldegrun AS, et al. G250: A Carbonic Anhydrase IX Monoclonal Antibody. Curr Oncol Rep 2005; 7: 109-15.
57. Steffens MG, Boerman OC, de Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5: 3268s-3274s.
58. Brouwers AH, Molders PFA, de Mulder PHM, et al. Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma. J Clin Oncol 2005; 23: 6540-6548.
59. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 57-62.
60. Brouwers AH, Buijs WC, Mulders PF, et al. Radioimmunotherapy with [1311]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res 2005; 11: 7178s-7186s.
61. Brouwers A, Verel J, Van Eerd J, et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 2004; 19: 155-63.